Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 9/20 | 0.42 |
| ▸ | CALCA | P06881 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | HTR7 | P34969 | 6/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.41 |
| ▸ | CALCB | P10092 | 1/20 | 0.38 |
| ▸ | ADM2 | Q7Z4H4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634875 | 0.82 | HTR7 (0.41) | HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL6637338 | 0.81 | HTR1A (0.36) | HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL15999444 | 0.80 | CALCA (0.44) | CALCRLCALCA | |
| SCHEMBL30087869 | 0.80 | CALCA (0.44) | CALCRLCALCA | |
| SCHEMBL15699749 | 0.80 | CALCA (0.44) | CALCRLCALCA | |
| SCHEMBL31456516 | 0.80 | CALCA (0.44) | CALCRLCALCA | |
| SCHEMBL6638270 | 0.80 | HTR7 (0.60) | HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL6636447 | 0.80 | HTR7 (0.60) | HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL6635868 | 0.80 | HTR7 (0.60) | HTR1AHTR2AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL6642177 | 0.80 | HTR1A (0.36) | HTR1AHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1426375-A2 | Analgesic spiroindole derivatives | AstraZeneca AB (SE) | 2004-06-09 | — | — | EP | claimed |
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | claimed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | claimed |
| US-6774132-B1 | Spirooxindole derivatives that act as analgesics | ASTRAZENECA AB (SE) | 2004-08-10 | — | — | US | disclosed |
| EP-1426375-A2 | Analgesic spiroindole derivatives | AstraZeneca AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1202994-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005790-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | OPRK1, OPRD1, OPRL1 | CALCRL 420/4885CALCA 506/4885HTR1A 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.